Retinitis pigmentosa

Retinitis pigmentosa is a group of related eye disorders that cause progressive vision loss. These disorders affect the retina, which is the layer of light-sensitive tissue at the back of the eye. In people with retinitis pigmentosa, vision loss occurs as the light-sensing cells of the retina gradually deteriorate.

The first sign of retinitis pigmentosa is usually a loss of night vision, which becomes apparent in childhood. Problems with night vision can make it difficult to navigate in low light. Later, the disease causes blind spots to develop in the side (peripheral) vision. Over time, these blind spots merge to produce tunnel vision. The disease progresses over years or decades to affect central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. In adulthood, many people with retinitis pigmentosa become legally blind.

The signs and symptoms of retinitis pigmentosa are most often limited to vision loss. When the disorder occurs by itself, it is described as nonsyndromic. Researchers have identified several major types of nonsyndromic retinitis pigmentosa, which are usually distinguished by their pattern of inheritance: autosomal dominant, autosomal recessive, or X-linked.

Less commonly, retinitis pigmentosa occurs as part of syndromes that affect other organs and tissues in the body. These forms of the disease are described as syndromic. The most common form of syndromic retinitis pigmentosa is Usher syndrome, which is characterized by the combination of vision loss and hearing loss beginning early in life. Retinitis pigmentosa is also a feature of several other genetic syndromes, including Bardet-Biedl syndrome; Refsum disease; and neuropathy, ataxia, and retinitis pigmentosa (NARP).

Frequency

Retinitis pigmentosa is one of the most common inherited diseases of the retina (retinopathies). It is estimated to affect 1 in 3,500 to 1 in 4,000 people in the United States and Europe.

Genetic Changes

Mutations in more than 60 genes are known to cause nonsyndromic retinitis pigmentosa. More than 20 of these genes are associated with the autosomal dominant form of the disorder. Mutations in the RHO gene are the most common cause of autosomal dominant retinitis pigmentosa, accounting for 20 to 30 percent of all cases. At least 35 genes have been associated with the autosomal recessive form of the disorder. The most common of these is USH2A; mutations in this gene are responsible for 10 to 15 percent of all cases of autosomal recessive retinitis pigmentosa. Changes
in at least six genes are thought to cause the X-linked form of the disorder. Together, mutations in the \textit{RPGR} and \textit{RP2} genes account for most cases of X-linked retinitis pigmentosa.

The genes associated with retinitis pigmentosa play essential roles in the structure and function of specialized light receptor cells (photoreceptors) in the retina. The retina contains two types of photoreceptors, rods and cones. Rods are responsible for vision in low light, while cones provide vision in bright light, including color vision.

Mutations in any of the genes responsible for retinitis pigmentosa lead to a gradual loss of rods and cones in the retina. The progressive degeneration of these cells causes the characteristic pattern of vision loss that occurs in people with retinitis pigmentosa. Rods typically break down before cones, which is why night vision impairment is usually the first sign of the disorder. Daytime vision is disrupted later, as both rods and cones are lost.

Some of the genes associated with retinitis pigmentosa are also associated with other eye diseases, including a condition called cone-rod dystrophy. Cone-rod dystrophy has signs and symptoms similar to those of retinitis pigmentosa. However, cone-rod dystrophy is characterized by deterioration of the cones first, followed by the rods, so daylight and color vision are affected before night vision.

\textbf{Inheritance Pattern}

Retinitis pigmentosa often has an autosomal dominant inheritance pattern, which means one copy of an altered gene in each cell is sufficient to cause the disorder. Most people with autosomal dominant retinitis pigmentosa have an affected parent and other family members with the disorder.

Retinitis pigmentosa can also have an autosomal recessive pattern of inheritance, which means both copies of a gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

This condition can also be inherited in an X-linked pattern. The genes associated with X-linked retinitis pigmentosa are located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females, (who have two X chromosomes), mutations usually have to occur in both copies of the gene to cause the disorder. However, at least 20 percent of females who carry only one mutated copy of the gene develop retinal degeneration and associated vision loss. In most cases, males experience more severe symptoms of the disorder than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

In 10 to 40 percent of all cases of retinitis pigmentosa, only one person in a family is affected. In these families, the disorder is described as simplex. It can be difficult to determine the inheritance pattern of simplex cases because affected individuals may have no affected relatives or may be unaware of other family members with the
disease. Simplex cases can also result from a new gene mutation that is not present in other family members.

**Other Names for This Condition**

- pigmentary retinopathy
- rod-cone dystrophy
- RP
- tapetoretinal degeneration

**Diagnosis & Management**

**Genetic Testing**

- Genetic Testing Registry: Retinitis pigmentosa

**Other Diagnosis and Management Resources**

- American Foundation for the Blind: Living with Vision Loss
  http://www.afb.org/info/living-with-vision-loss/2
- Foundation Fighting Blindness: Treatment of Retinitis Pigmentosa
  http://www.blindness.org/retinitis-pigmentosa#treatments
- GeneReview: Nonsyndromic Retinitis Pigmentosa Overview
  https://www.ncbi.nlm.nih.gov/books/NBK1417
- RP Fighting Blindness: Treatment of Retinitis Pigmentosa

**General Information from MedlinePlus**

- Diagnostic Tests
  https://medlineplus.gov/diagnostictests.html
- Drug Therapy
  https://medlineplus.gov/drugtherapy.html
- Genetic Counseling
  https://medlineplus.gov/geneticcounseling.html
- Palliative Care
  https://medlineplus.gov/palliativecare.html
- Surgery and Rehabilitation
  https://medlineplus.gov/surgeryandrehabilitation.html
Additional Information & Resources

MedlinePlus

- Encyclopedia: Retinitis Pigmentosa
  https://medlineplus.gov/ency/article/001029.htm
- Health Topic: Retinal Disorders
  https://medlineplus.gov/retinaldisorders.html

Genetic and Rare Diseases Information Center

- Cone-rod dystrophy
- Retinitis pigmentosa
  https://rarediseases.info.nih.gov/diseases/5694/retinitis-pigmentosa

Additional NIH Resources

- National Eye Institute: Diagram of the Eye
  https://nei.nih.gov/health/eyediagram/
- National Human Genome Research Institute
  https://www.genome.gov/13514348/

Educational Resources

- MalaCards: retinitis pigmentosa
  http://www.malacards.org/card/retinitis_pigmentosa
- My46 Trait Profile
  https://www.my46.org/trait-document?trait=Retinitis%20Pigmentosa&type=profile
- Ohio State University Medical Center
  https://wexnermedical.osu.edu/eye-care-ophthalmology/retinal-disorders
- Orphanet: Retinitis pigmentosa
  http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=791
- The Merck Manual Home Edition for Patients and Caregivers
  https://www.merckmanuals.com/home/eye-disorders/retinal-disorders/retinitis-pigmentosa

Patient Support and Advocacy Resources

- American Foundation for the Blind
  https://www.afb.org/default.aspx
- Foundation Fighting Blindness
  http://www.blindness.org/retinitis-pigmentosa
- National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/retinitis-pigmentosa/
• Prevent Blindness America
https://www.preventblindness.org/retinitis-pigmentosa

• Resource list from the University of Kansas Medical Center
http://www.kumc.edu/gec/support/retiniti.html

• Retina International
http://www.retina-international.org/patients/rare-conditions/retinitis-pigmentosa

• RP Fighting Blindness: The British Retinitis Pigmentosa Society
https://www.rpfightingblindness.org.uk/home.php?home=yes

GeneReviews
• Nonsyndromic Retinitis Pigmentosa Overview
https://www.ncbi.nlm.nih.gov/books/NBK1417

ClinicalTrials.gov
• ClinicalTrials.gov
https://clinicaltrials.gov/ct2/results?cond=%22retinitis+pigmentosa%22

Scientific Articles on PubMed
• PubMed
https://www.ncbi.nlm.nih.gov/pubmed/?term=%28Retinitis+Pigmentosa%5BMAJR%29+%5D%29+AND+%28retinitis+pigmentosa%5BTI%5D%29+AND+english%5BLa%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22+AND+english%5Bdp%5D

OMIM
• RETINITIS PIGMENTOSA
http://omim.org/entry/268000

Sources for This Summary
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17296890
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2580741/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18188946
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582019/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301590

page 5
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17032466
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1621055/

• Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006 Nov 18;368(9549):1795-809. Review. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17113430

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16969763

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16799052
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585061/


Reviewed: October 2010
Published: April 25, 2018

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services